查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1917130

患者來源異種移植模型市場報告：趨勢、預測和競爭分析（至2031年）

Patient-derived Xenograft Model Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 205 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

由於製藥和生物製藥公司、學術和研究機構以及合約研究組織/合約開發生產組織（CRO/CDMO）的機會，全球患者來源異種移植模型市場預計將保持強勁成長。預計2025年至2031年，全球患者來源異種移植模型市場將以9.6%的年複合成長率成長。該市場的主要促進因素包括：對個人化癌症研究的需求不斷成長、臨床前腫瘤模型的應用日益廣泛以及對標靶藥物研發的日益重視。

  • 根據 Lucintel 的預測，在預測期內，乳癌預計將成為所有腫瘤類型中成長最快的腫瘤。
  • 依最終用途分類，CRO/CDMO 預計將呈現最高的成長率。
  • 從地區來看，預計北美在預測期內將出現最高的成長率。

患者來源異種移植模型市場的新趨勢

受個人化醫療、癌症研究和藥物研發領域進展的推動，患者來源的異種移植模型市場正經歷快速成長。隨著研究人員尋求能夠更準確地預測臨床結果的模型，該市場也在不斷發展，創新技術的應用以及製藥公司和學術機構的日益普及推動了市場的發展。這些進步改變癌症治療方法的測試方式和個人化治療方案的開發，最終將帶來更好的治療效果和更低的成本。以下關鍵趨勢突顯了塑造該市場的動態變化，並反映了生物醫學研究和藥物發現領域向更精準、高效和協作方法的轉變。

  • 腫瘤學研究中PDX模型的應用日益廣泛：與傳統細胞株相比，PDX模型能更準確地代表人類腫瘤，因此市場對PDX模型的需求日益成長。這一趨勢的驅動力在於需要對癌症藥物進行更有效的臨床前測試，以提高臨床試驗的成功率。製藥公司和研究機構正大力投資PDX模型，以期發現有效的治療方法、制定個人化的治療方案並了解腫瘤的異質性。提高PDX模型可用性和可靠性的技術進步也推動了其應用，加速了癌症研究和開發進程。
  • 基因組和分子譜分析的整合：將基因組和分子資料與PDX模型整合，變革個人化醫療。對腫瘤進行基因分析，使研究人員能夠選擇反映特定患者特徵的最佳PDX模型。這種方法提高了臨床前研究的預測準確性，並促進了標靶治療的開發。定序技術和生物資訊學的進步推動這種整合，實現更精準的治療策略。因此，這一趨勢提高了將臨床前研究成果轉化為有效臨床干預措施的成功率，最終有助於改善患者的治療效果。
  • PDX模型開發中的技術創新：人源化PDX模型、3D生物列印和微流體系統等創新技術提高PDX模型的保真度和功能性。整合了人體免疫系統的人源化模型增強了免疫療法評估的準確性。 3D生物列印技術能夠建構複雜的腫瘤微環境，而微流體平台則有助於進行高通量測試。這些技術進步使PDX模型能夠更真實地模擬人體腫瘤，縮小臨床前研究結果與臨床結果之間的差距。因此，市場增加對先進技術的投資，以提高模型的準確性和預測能力。
  • 對倫理和監管方面的關注日益增加：隨著PDX模型應用範圍的擴大，動物福利和監管合規的倫理考量變得癒合重要。標準化通訊協定和指南製定中，以確保動物得到妥善對待並獲得可重複的結果。監管機構也在努力簡化基於PDX的研究和治療方法的核准流程。這種對倫理和監管的重視增強相關人員之間的信任和接受度，促進PDX模型在臨床研究中的廣泛應用。它也有助於推動負責任的創新，確保技術進步符合社會和倫理標準。
  • 拓展合作研究與資料共用：PDX市場正加速邁向合作研究與開放資料共用的趨勢。學術機構、生物技術公司和製藥公司之間的合作，促進了對多樣化腫瘤模型和大型資料集的獲取。共用的資料庫和平台使研究人員能夠檢驗、減少重複研究並加速發現。這種合作模式提高了臨床前研究的可靠性，並促進了創新。隨著資料共用的日益普及，預計將加速有效治療方法的開發，降低成本，並提高PDX市場的整體研究效率。

總而言之，這些新興趨勢共同重塑患者來源的異種移植模型市場，使研究更加嚴謹、合乎倫理、更具創新性和協作性，推動更有效的個人化治療方法的開發，縮短藥物開發時間，改善患者預後，並最終改變癌症研究和治療的格局。

患者來源異種移植模型市場的最新趨勢

在癌症研究、個人化醫療和藥物研發的推動下，患者來源的異種移植模型市場正經歷顯著成長。隨著研究人員尋求能夠更準確地預測臨床結果的模型，技術創新以及研究和製藥公司對該模型的日益普及迅速推動市場發展。這些進步透過實現更具針對性的治療和改善患者預後，塑造腫瘤學研究的未來。以下關鍵進展突顯了這個充滿活力的市場近期的趨勢和變化。

  • 擴展 PDX 模型庫：建立廣泛且多樣化的PDX 庫，透過提供更廣泛的腫瘤類型和基因譜，增強研究能力，實現更精確的藥物測試和個人化治療策略，加速標靶治療的開發，縮短上市時間。
  • 基因組技術的整合：將先進的基因組和分子分析工具整合到PDX模型中，有助於更深入了解腫瘤異質性和抗藥性機制。這種整合使研究人員能夠識別生物標記，並更有效地實現個人化治療，提高臨床成功率並改善患者預後。
  • 人源化PDX模型的引進：整合了人類免疫系統成分的人源化PDX模型的發展徹底改變了免疫療法的研究。這些模型能夠更準確地模擬人類免疫反應，促進免疫腫瘤藥物的測試並加速其臨床開發。
  • 自動化和人工智慧的應用日益廣泛：自動化和人工智慧正用於簡化PDX模型開發、資料分析和藥物篩檢流程。這些技術的整合透過降低成本、提高可重複性和加快研究工作流程，顯著提升了藥物發現和開發的效率。
  • 監管和倫理方面的進展：不斷發展的法規結構和倫理標準推動PDX模型的更廣泛應用。明確的指導方針和監管機構日益成長的認可度加快PDX模型藥物的核准流程，最終使患者能夠更早獲得創新治療方法而受益。

總之，這些近期趨勢正透過提高模型準確性、拓展研究能力和加速藥物研發進程，顯著影響患者來源異種移植模型市場。基因組技術、人源化模型、自動化和監管支援的整合推動創新，並提高PDX模型的有效性和可用性。因此，這些進展有望促進個人化醫療方法的改進，並改善癌症治療及其他領域的臨床療效。

目錄

第1章 執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球病患來源異種移植模型市場（依腫瘤類型）

  • 吸引力分析：依腫瘤類型
  • 肺癌
  • 胰臟癌
  • 攝護腺癌
  • 乳癌
  • 其他

第5章 全球病患來源異種移植模型市場（依模型類型）

  • 吸引力分析：依車型類型
  • 小鼠模型
  • 大鼠模型

第6章 全球病患來源異種移植模型市場（依最終用途）

  • 吸引力分析：依最終用途分類
  • 製藥和生物製藥公司
  • 學術和研究機構
  • CRO/CDMO

第7章 區域分析

第8章 北美患者來源異種移植模型市場

  • 北美患者來源異種移植模型市場（依腫瘤類型）
  • 北美患者來源異種移植模型市場（依最終用途）
  • 美國患者來源異種移植模型市場
  • 墨西哥患者來源異種移植模型市場
  • 加拿大患者來源異種移植模型市場

第9章 歐洲病患來源異種移植模型市場

  • 歐洲患者來源異種移植模型市場（依腫瘤類型）
  • 歐洲患者來源異種移植模型市場（依最終用途）
  • 德國患者來源異種移植模型市場
  • 法國患者來源異種移植模型市場
  • 西班牙患者來源異種移植模型市場
  • 義大利患者來源異種移植模型市場
  • 英國患者來源異種移植模型市場

第10章 亞太地區病患來源異種移植模型市場

  • 亞太地區患者來源異種移植模型市場（依腫瘤類型）
  • 亞太地區患者來源異種移植模型市場（依最終用途）
  • 日本患者來源異種移植模型市場
  • 印度患者來源異種移植模型市場
  • 中國患者來源異種移植模型市場
  • 韓國患者來源異種移植模型市場
  • 印尼患者來源異種移植模型市場

第11章 世界其他地區（ROW）患者來源異種移植模型市場

  • ROW 患者來源異種移植模型市場（依腫瘤類型）
  • ROW患者來源異種移植模型市場（依最終用途）
  • 中東病患來源異種移植模型市場
  • 南美洲患者來源異種移植模型市場
  • 非洲患者來源異種移植模型市場

第12章 競爭分析

  • 產品系列分析
  • 運作整合
  • 波特五力分析
  • 市場佔有率分析

第13章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 全球患者來源異種移植模型市場的新趨勢
  • 戰略分析

第14章 價值鏈中主要企業的概況

  • 競爭分析：概述
  • Charles River Laboratories
  • The Jackson Laboratory
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • WuXi AppTec
  • Oncodesign
  • Hera Biolabs
  • XenTech
  • Abnova Corp.

第15章 附錄

The future of the global patient-derived xenograft model market looks promising with opportunities in the pharmaceutical & biopharmaceutical company, academic & research institute, and CRO & CDMO markets. The global patient-derived xenograft model market is expected to grow with a CAGR of 9.6% from 2025 to 2031. The major drivers for this market are the increasing demand for personalized cancer research, the rising adoption of preclinical oncology models, and the growing focus on targeted drug development.

  • Lucintel forecasts that, within the tumor type category, breast cancer is expected to witness the highest growth over the forecast period.
  • Within the end use category, CRO & CDMO is expected to witness the highest growth.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Patient-derived Xenograft Model Market

The patient-derived xenograft model market is experiencing rapid growth driven by advancements in personalized medicine, cancer research, and drug development. As researchers seek more accurate models to predict clinical outcomes, the market is evolving with innovative technologies and increasing adoption across pharmaceutical and academic institutions. These developments are transforming how cancer therapies are tested and tailored to individual patients, ultimately improving treatment efficacy and reducing costs. The following key trends highlight the dynamic changes shaping this market, reflecting a shift towards more precise, efficient, and collaborative approaches in biomedical research and drug discovery.

  • Increasing Adoption of PDX Models in Oncology Research: The demand for PDX models is rising as they provide a more accurate representation of human tumors compared to traditional cell lines. This trend is driven by the need for better preclinical testing of anticancer drugs, leading to higher success rates in clinical trials. Pharmaceutical companies and research institutions are investing heavily in PDX models to identify effective therapies, personalize treatment plans, and understand tumor heterogeneity. The growing adoption is also supported by technological improvements that make PDX models more accessible and reliable, thereby accelerating cancer research and drug development processes.
  • Integration of Genomic and Molecular Profiling: The integration of genomic and molecular data with PDX models is transforming personalized medicine. By analyzing tumor genetics, researchers can select the most appropriate PDX models that mirror specific patient profiles. This approach enhances the predictive power of preclinical studies, enabling the development of targeted therapies. Advances in sequencing technologies and bioinformatics are facilitating this integration, leading to more precise treatment strategies. Consequently, this trend is improving the success rate of translating preclinical findings into effective clinical interventions, ultimately benefiting patient outcomes.
  • Technological Innovations in PDX Model Development: Innovations such as humanized PDX models, 3D bioprinting, and microfluidic systems are enhancing the fidelity and functionality of PDX models. Humanized models, which incorporate human immune systems, allow for better evaluation of immunotherapies. 3D bioprinting enables the creation of complex tumor microenvironments, while microfluidic platforms facilitate high-throughput testing. These technological advancements are making PDX models more representative of actual human tumors, reducing the gap between preclinical and clinical results. As a result, the market is witnessing increased investment in cutting-edge technologies to improve model accuracy and predictive capabilities.
  • Growing Focus on Ethical and Regulatory Aspects: As the use of PDX models expands, ethical considerations regarding animal welfare and regulatory compliance are gaining prominence. Efforts are underway to develop standardized protocols and guidelines to ensure humane treatment of animals and reproducibility of results. Regulatory agencies are also working to streamline approval processes for PDX-based research and therapies. This focus on ethics and regulation is fostering greater trust and acceptance among stakeholders, encouraging wider adoption of PDX models in clinical research. It also promotes responsible innovation, ensuring that advancements align with societal and ethical standards.
  • Expansion of Collaborative Research and Data Sharing: The trend towards collaborative research and open data sharing is accelerating in the PDX market. Partnerships between academia, biotech firms, and pharmaceutical companies facilitate access to diverse tumor models and large datasets. Shared repositories and platforms enable researchers to validate findings, reduce duplication, and accelerate discovery. This collaborative approach enhances the robustness of preclinical studies and fosters innovation. As data sharing becomes more prevalent, it is expected to lead to more rapid development of effective therapies, reduce costs, and improve overall research efficiency in the PDX market.

In summary, these emerging trends are collectively reshaping the Patient-derived Xenograft Model Market by making research more precise, ethical, innovative, and collaborative. They are driving the development of more effective personalized therapies, reducing drug development timelines, and improving patient outcomes, ultimately transforming the landscape of cancer research and treatment.

Recent Developments in the Patient-derived Xenograft Model Market

The patient-derived xenograft model market has experienced significant growth driven by advancements in cancer research, personalized medicine, and drug development. As researchers seek more accurate models to predict clinical outcomes, the market is evolving rapidly with technological innovations and increased adoption across research institutions and pharmaceutical companies. These developments are shaping the future landscape of oncology research, enabling more targeted therapies and improving patient outcomes. The following key developments highlight the recent trends and shifts within this dynamic market.

  • Expansion of PDX Model Libraries: : The creation of extensive, diverse PDX repositories has enhanced research capabilities by providing a broader spectrum of tumor types and genetic profiles. This expansion allows for more precise drug testing and personalized treatment strategies, accelerating the development of targeted therapies and reducing time-to-market for new drugs.
  • Integration of Genomic Technologies: : Incorporating advanced genomic and molecular profiling tools into PDX models has improved understanding of tumor heterogeneity and resistance mechanisms. This integration enables researchers to identify biomarkers and tailor treatments more effectively, leading to more successful clinical translations and improved patient outcomes.
  • Adoption of Humanized PDX Models: : The development of humanized PDX models, which incorporate human immune system components, has revolutionized immunotherapy research. These models provide a more accurate representation of human immune responses, facilitating the testing of immuno-oncology drugs and accelerating their clinical development.
  • Increased Use of Automation and AI: : Automation and artificial intelligence are being employed to streamline PDX model development, data analysis, and drug screening processes. This technological integration reduces costs, enhances reproducibility, and speeds up research workflows, thereby increasing the efficiency of drug discovery and development.
  • Regulatory and Ethical Advancements: : Evolving regulatory frameworks and ethical standards are supporting the broader adoption of PDX models. Clear guidelines and increased acceptance by regulatory agencies are facilitating faster approval processes for drugs tested using PDX models, ultimately benefiting patients through quicker access to innovative therapies.

In summary, these recent developments are significantly impacting the Patient-derived Xenograft Model Market by improving model accuracy, expanding research capabilities, and accelerating drug development. The integration of genomic technologies, humanized models, automation, and regulatory support are collectively driving innovation, making PDX models more effective and accessible. Consequently, these advancements are poised to enhance personalized medicine approaches and improve clinical outcomes in oncology and beyond.

Strategic Growth Opportunities in the Patient-derived Xenograft Model Market

The patient-derived xenograft model market is experiencing rapid growth driven by advancements in personalized medicine, cancer research, and drug development. As researchers seek more accurate models to predict clinical outcomes, the demand for PDX models is increasing across various applications. This expansion is fueled by technological innovations, increasing investment in oncology research, and the need for targeted therapies. The market's evolution presents significant opportunities for pharmaceutical companies, research institutions, and biotech firms to develop more effective treatments. Understanding key growth areas across different applications can help stakeholders capitalize on emerging trends and accelerate the development of innovative solutions.

  • Oncology Drug Development: The increasing need for predictive preclinical models is driving the adoption of PDX models in oncology drug testing. These models closely mimic human tumor biology, enabling more accurate assessment of drug efficacy and safety. This leads to faster, more reliable clinical translation, reducing drug development costs and timeframes. The impact is a more efficient pipeline for new cancer therapies, ultimately benefiting patients through quicker access to innovative treatments.
  • Personalized Medicine: PDX models are crucial for developing personalized treatment plans by testing individual patient tumor responses to various therapies. This application enhances precision medicine, allowing clinicians to tailor treatments based on specific tumor characteristics. The impact is improved treatment outcomes, reduced adverse effects, and increased confidence in therapy selection, fostering a shift toward more individualized cancer care.
  • Biomarker Discovery: The use of PDX models in identifying novel biomarkers is expanding, aiding in early diagnosis and prognosis of cancers. These models help validate potential biomarkers in a biologically relevant environment, accelerating their clinical application. The impact includes improved diagnostic accuracy, better patient stratification, and the development of targeted therapies, ultimately advancing personalized treatment strategies.
  • Immuno-oncology Research: PDX models are increasingly integrated with humanized immune systems to study immune responses and evaluate immunotherapies. This application provides insights into tumor-immune interactions and helps optimize immunotherapeutic agents. The impact is the development of more effective immunotherapies, leading to improved patient response rates and expanding treatment options in oncology.
  • Metastasis and Tumor Microenvironment Studies: PDX models are instrumental in understanding tumor metastasis and the tumor microenvironment. They enable researchers to investigate mechanisms of cancer spread and resistance, facilitating the development of anti-metastatic therapies. The impact is the potential to prevent or limit metastasis, improving survival rates and quality of life for cancer patients.

In summary, these growth opportunities are significantly shaping the Patient-derived Xenograft Model Market by enhancing drug development, personalized treatment, and understanding of cancer biology. The expansion across key applications is driving innovation, reducing development costs, and improving patient outcomes, positioning the market for sustained growth and impact in oncology research and therapy development.

Patient-derived Xenograft Model Market Driver and Challenges

The patient-derived xenograft model market is influenced by a variety of technological, economic, and regulatory factors. Advances in personalized medicine and cancer research have heightened demand for more accurate preclinical models, driving innovation and growth. Economic factors such as increased healthcare spending and funding for biomedical research further propel market expansion. Regulatory frameworks aimed at improving research standards and ethical considerations also shape market dynamics. However, challenges such as high development costs, complex regulatory approval processes, and ethical concerns surrounding animal models pose significant hurdles. Understanding these drivers and challenges is essential for stakeholders to navigate the evolving landscape effectively.

The factors responsible for driving the patient-derived xenograft model market include:

  • Technological Advancements: The integration of genomic sequencing and biotechnological innovations has significantly improved the development of PDX models. These advancements enable more precise tumor engraftment and characterization, leading to better predictive accuracy for drug responses. As technology continues to evolve, the efficiency and reliability of PDX models increase, attracting pharmaceutical companies and research institutions. This progress accelerates drug discovery, personalized treatment strategies, and biomarker identification, thereby expanding the market. The ongoing innovation ensures that PDX models remain at the forefront of translational cancer research, fostering sustained growth.
  • Rising Prevalence of Cancer: The increasing incidence of various cancers globally is a major driver for the PDX market. As cancer cases rise, there is a growing need for effective preclinical models to evaluate new therapies. PDX models, which closely mimic human tumor biology, are invaluable in understanding disease progression and testing targeted treatments. This demand is further amplified by the shift towards personalized medicine, requiring models that reflect individual patient tumor characteristics. Consequently, the market experiences heightened adoption and investment, supporting the development of more sophisticated PDX platforms to meet clinical and research needs.
  • Growing Investment in Oncology Research: Increased funding from government agencies, private investors, and pharmaceutical companies is fueling the PDX market. These investments aim to accelerate the development of novel cancer therapies and improve existing treatment options. The focus on translational research and precision medicine has led to substantial financial support for establishing and expanding PDX repositories. This influx of capital enables research institutions to develop more diverse and representative models, facilitating faster drug screening and validation. As a result, the market benefits from enhanced research capabilities and a broader pipeline of potential therapeutics.
  • Regulatory Support and Standardization: Regulatory agencies are increasingly recognizing the importance of PDX models in drug development and approval processes. Initiatives to establish standardized protocols and validation procedures improve reproducibility and reliability of research outcomes. Regulatory support encourages pharmaceutical companies to incorporate PDX models into their preclinical testing, reducing the risk of late-stage failures. This environment fosters confidence among stakeholders and promotes broader adoption of PDX technologies. As regulations evolve to facilitate ethical and efficient research, the market experiences growth driven by increased compliance and trust.
  • Expansion of Personalized Medicine: The shift towards personalized treatment approaches in oncology is a significant market driver. PDX models enable the testing of therapies tailored to individual patient tumors, improving treatment efficacy and reducing adverse effects. This personalized approach necessitates the development of diverse and patient-specific models, expanding the scope and application of PDX technology. The demand for such models encourages collaborations between research institutions and biotech firms, fostering innovation. As healthcare providers increasingly adopt personalized strategies, the market for PDX models is expected to grow substantially, supporting more targeted and effective cancer treatments.

The challenges facing the patient-derived xenograft model market include:

  • High Development and Maintenance Costs: Developing and maintaining PDX models is resource-intensive, requiring significant financial investment. The costs associated with tumor sample collection, model establishment, and ongoing animal care are substantial. These expenses can limit accessibility for smaller research entities and slow down the pace of innovation. Additionally, the need for specialized facilities and skilled personnel further escalates costs. High expenses may also impact the affordability and scalability of PDX models, hindering widespread adoption and limiting their integration into routine drug development processes.
  • Complex Regulatory and Ethical Issues: The use of animal models raises ethical concerns and faces stringent regulatory scrutiny. Ethical debates surrounding animal welfare and the necessity of animal testing pose challenges for researchers and companies. Regulatory approval processes for PDX-based studies can be lengthy and complex, delaying research timelines and increasing costs. Variability in regulations across regions adds further complexity, complicating international collaborations. These issues can impede the rapid development and deployment of PDX models, affecting market growth and innovation.
  • Limited Predictive Power and Tumor Heterogeneity: Despite their advantages, PDX models have limitations in fully replicating human tumor heterogeneity and microenvironment. Variability in engraftment success and differences between patient tumors and models can affect predictive accuracy. This limitation may lead to discrepancies in drug response data, impacting clinical translation. Additionally, the time required to establish PDX models can delay research and decision-making. Overcoming these scientific challenges is crucial for enhancing the reliability and utility of PDX models, which directly influences market confidence and expansion.

In summary, the Patient-derived Xenograft Model Market is driven by technological innovations, rising cancer prevalence, increased research investments, regulatory support, and the shift towards personalized medicine. However, high costs, ethical and regulatory complexities, and scientific limitations pose significant challenges. These factors collectively shape the market landscape, requiring stakeholders to balance innovation with ethical and financial considerations. The overall impact is a dynamic environment with substantial growth potential, provided that scientific and regulatory hurdles are effectively addressed. Continued advancements and strategic collaborations will be essential for unlocking the full potential of PDX models in cancer research and therapy development.

List of Patient-derived Xenograft Model Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies patient-derived xenograft model companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the patient-derived xenograft model companies profiled in this report include-

  • Charles River Laboratories
  • The Jackson Laboratory
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • WuXi AppTec
  • Oncodesign
  • Hera Biolabs
  • XenTech
  • Abnova Corp.

Patient-derived Xenograft Model Market by Segment

The study includes a forecast for the global patient-derived xenograft model market by tumor type, model type, end use, and region.

Patient-derived Xenograft Model Market by Tumor Type [Value from 2019 to 2031]:

  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Breast Cancer
  • Others

Patient-derived Xenograft Model Market by Model Type [Value from 2019 to 2031]:

  • Mice Model
  • Rat Model

Patient-derived Xenograft Model Market by End Use [Value from 2019 to 2031]:

  • Pharmaceutical & Biopharmaceutical Companies
  • Academic & Research Institutes
  • CRO's & CDMO's

Patient-derived Xenograft Model Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Patient-derived Xenograft Model Market

The patient-derived xenograft model market has experienced significant growth driven by advancements in personalized medicine, cancer research, and drug development. As researchers seek more accurate models to predict clinical outcomes, countries are investing in innovative technologies and expanding their research capabilities. The United States, China, Germany, India, and Japan are leading this evolution, each contributing unique developments to enhance the understanding and application of PDX models. These countries are focusing on technological integration, regulatory support, and expanding research infrastructure to accelerate market growth and improve patient outcomes worldwide.

  • United States: The US remains at the forefront of PDX model development, with increased funding from government agencies like the NIH and private sector investments. Recent advancements include the integration of genomic profiling with PDX models to personalize cancer treatments. Several biotech firms are developing high-throughput PDX platforms, improving drug screening efficiency. Regulatory agencies are also working on guidelines to streamline PDX-based drug approval processes, fostering faster clinical translation. The US's robust research ecosystem continues to drive innovation and market expansion in this sector.
  • China: China has rapidly expanded its PDX market, driven by government initiatives supporting biotech innovation and cancer research. Recent developments include the establishment of specialized PDX research centers and increased collaborations between academia and industry. Chinese companies are focusing on developing cost-effective, scalable PDX models tailored to prevalent cancers like lung and gastric cancers. The country is also investing in automation and AI-driven data analysis to enhance model accuracy and throughput. These efforts aim to position China as a major player in global PDX research and drug development.
  • Germany: Germany emphasizes precision medicine and has made notable progress in integrating PDX models into clinical research. Recent advancements include the development of patient-specific PDX models for rare cancers, aiding personalized treatment strategies. German biotech firms are adopting advanced imaging and molecular techniques to improve model characterization. The country benefits from strong regulatory frameworks that facilitate clinical translation of PDX-based therapies. Additionally, collaborations between academic institutions and industry are fostering innovation, positioning Germany as a key contributor to the European PDX market.
  • India: India is witnessing rapid growth in the PDX market, supported by increasing cancer prevalence and a focus on affordable research solutions. Recent developments include the establishment of research hubs dedicated to PDX model development and validation. Indian biotech companies are working on cost-effective, scalable PDX models to support local drug discovery efforts. The government's initiatives to promote biotech innovation and collaborations with international research organizations are accelerating progress. Efforts are also underway to adapt PDX models for a broader range of cancers prevalent in the Indian population, aiming to improve treatment outcomes.
  • Japan: Japan has made significant strides in integrating PDX models into its cancer research landscape. Recent advancements include the development of genetically engineered PDX models that better mimic human tumor biology. Japanese research institutions are focusing on combining PDX models with cutting-edge technologies like single-cell sequencing and AI analytics. The country's strong regulatory environment supports clinical translation and commercialization of PDX-based therapies. Japan's emphasis on precision medicine and innovative research collaborations continues to propel the growth of the PDX market, positioning it as a leader in Asia.

Features of the Global Patient-derived Xenograft Model Market

  • Market Size Estimates: Patient-derived xenograft model market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Patient-derived xenograft model market size by tumor type, model type, end use, and region in terms of value ($B).
  • Regional Analysis: Patient-derived xenograft model market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different tumor types, model types, end uses, and regions for the patient-derived xenograft model market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the patient-derived xenograft model market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the patient-derived xenograft model market by tumor type (lung cancer, pancreatic cancer, prostate cancer, breast cancer, and others), model type (mice model and rat model), end use (pharmaceutical & biopharmaceutical companies, academic & research institutes, and CRO's & CDMO's), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Patient-derived Xenograft Model Market by Tumor Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Tumor Type
  • 4.3 Lung Cancer : Trends and Forecast (2019-2031)
  • 4.4 Pancreatic Cancer : Trends and Forecast (2019-2031)
  • 4.5 Prostate Cancer : Trends and Forecast (2019-2031)
  • 4.6 Breast Cancer : Trends and Forecast (2019-2031)
  • 4.7 Others : Trends and Forecast (2019-2031)

5. Global Patient-derived Xenograft Model Market by Model Type

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Model Type
  • 5.3 Mice Model : Trends and Forecast (2019-2031)
  • 5.4 Rat Model : Trends and Forecast (2019-2031)

6. Global Patient-derived Xenograft Model Market by End Use

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by End Use
  • 6.3 Pharmaceutical & Biopharmaceutical Companies : Trends and Forecast (2019-2031)
  • 6.4 Academic & Research Institutes : Trends and Forecast (2019-2031)
  • 6.5 CRO's & CDMO's : Trends and Forecast (2019-2031)

7. Regional Analysis

  • 7.1 Overview
  • 7.2 Global Patient-derived Xenograft Model Market by Region

8. North American Patient-derived Xenograft Model Market

  • 8.1 Overview
  • 8.2 North American Patient-derived Xenograft Model Market by Tumor Type
  • 8.3 North American Patient-derived Xenograft Model Market by End Use
  • 8.4 The United States Patient-derived Xenograft Model Market
  • 8.5 Canadian Patient-derived Xenograft Model Market
  • 8.6 Mexican Patient-derived Xenograft Model Market

9. European Patient-derived Xenograft Model Market

  • 9.1 Overview
  • 9.2 European Patient-derived Xenograft Model Market by Tumor Type
  • 9.3 European Patient-derived Xenograft Model Market by End Use
  • 9.4 German Patient-derived Xenograft Model Market
  • 9.5 French Patient-derived Xenograft Model Market
  • 9.6 Italian Patient-derived Xenograft Model Market
  • 9.7 Spanish Patient-derived Xenograft Model Market
  • 9.8 The United Kingdom Patient-derived Xenograft Model Market

10. APAC Patient-derived Xenograft Model Market

  • 10.1 Overview
  • 10.2 APAC Patient-derived Xenograft Model Market by Tumor Type
  • 10.3 APAC Patient-derived Xenograft Model Market by End Use
  • 10.4 Chinese Patient-derived Xenograft Model Market
  • 10.5 Indian Patient-derived Xenograft Model Market
  • 10.6 Japanese Patient-derived Xenograft Model Market
  • 10.7 South Korean Patient-derived Xenograft Model Market
  • 10.8 Indonesian Patient-derived Xenograft Model Market

11. ROW Patient-derived Xenograft Model Market

  • 11.1 Overview
  • 11.2 ROW Patient-derived Xenograft Model Market by Tumor Type
  • 11.3 ROW Patient-derived Xenograft Model Market by End Use
  • 11.4 Middle Eastern Patient-derived Xenograft Model Market
  • 11.5 South American Patient-derived Xenograft Model Market
  • 11.6 African Patient-derived Xenograft Model Market

12. Competitor Analysis

  • 12.1 Product Portfolio Analysis
  • 12.2 Operational Integration
  • 12.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

  • 13.1 Value Chain Analysis
  • 13.2 Growth Opportunity Analysis
    • 13.2.1 Growth Opportunity by Tumor Type
    • 13.2.2 Growth Opportunity by Model Type
    • 13.2.3 Growth Opportunity by End Use
  • 13.3 Emerging Trends in the Global Patient-derived Xenograft Model Market
  • 13.4 Strategic Analysis
    • 13.4.1 New Product Development
    • 13.4.2 Certification and Licensing
    • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

  • 14.1 Competitive Analysis Overview
  • 14.2 Charles River Laboratories
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.3 The Jackson Laboratory
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.4 Crown Bioscience
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.5 Altogen Labs
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.6 Envigo
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.7 WuXi AppTec
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.8 Oncodesign
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.9 Hera Biolabs
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.10 XenTech
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.11 Abnova Corp.
    • Company Overview
    • Patient-derived Xenograft Model Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

15. Appendix

  • 15.1 List of Figures
  • 15.2 List of Tables
  • 15.3 Research Methodology
  • 15.4 Disclaimer
  • 15.5 Copyright
  • 15.6 Abbreviations and Technical Units
  • 15.7 About Us
  • 15.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Patient-derived Xenograft Model Market
  • Figure 2.1: Usage of Patient-derived Xenograft Model Market
  • Figure 2.2: Classification of the Global Patient-derived Xenograft Model Market
  • Figure 2.3: Supply Chain of the Global Patient-derived Xenograft Model Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Patient-derived Xenograft Model Market
  • Figure 4.1: Global Patient-derived Xenograft Model Market by Tumor Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Patient-derived Xenograft Model Market ($B) by Tumor Type
  • Figure 4.3: Forecast for the Global Patient-derived Xenograft Model Market ($B) by Tumor Type
  • Figure 4.4: Trends and Forecast for Lung Cancer in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Pancreatic Cancer in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Prostate Cancer in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Breast Cancer in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 4.8: Trends and Forecast for Others in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 5.1: Global Patient-derived Xenograft Model Market by Model Type in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Patient-derived Xenograft Model Market ($B) by Model Type
  • Figure 5.3: Forecast for the Global Patient-derived Xenograft Model Market ($B) by Model Type
  • Figure 5.4: Trends and Forecast for Mice Model in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Rat Model in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 6.1: Global Patient-derived Xenograft Model Market by End Use in 2019, 2024, and 2031
  • Figure 6.2: Trends of the Global Patient-derived Xenograft Model Market ($B) by End Use
  • Figure 6.3: Forecast for the Global Patient-derived Xenograft Model Market ($B) by End Use
  • Figure 6.4: Trends and Forecast for Pharmaceutical & Biopharmaceutical Companies in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 6.5: Trends and Forecast for Academic & Research Institutes in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 6.6: Trends and Forecast for CRO's & CDMO's in the Global Patient-derived Xenograft Model Market (2019-2031)
  • Figure 7.1: Trends of the Global Patient-derived Xenograft Model Market ($B) by Region (2019-2024)
  • Figure 7.2: Forecast for the Global Patient-derived Xenograft Model Market ($B) by Region (2025-2031)
  • Figure 8.1: Trends and Forecast for the North American Patient-derived Xenograft Model Market (2019-2031)
  • Figure 8.2: North American Patient-derived Xenograft Model Market by Tumor Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the North American Patient-derived Xenograft Model Market ($B) by Tumor Type (2019-2024)
  • Figure 8.4: Forecast for the North American Patient-derived Xenograft Model Market ($B) by Tumor Type (2025-2031)
  • Figure 8.5: North American Patient-derived Xenograft Model Market by Model Type in 2019, 2024, and 2031
  • Figure 8.6: Trends of the North American Patient-derived Xenograft Model Market ($B) by Model Type (2019-2024)
  • Figure 8.7: Forecast for the North American Patient-derived Xenograft Model Market ($B) by Model Type (2025-2031)
  • Figure 8.8: North American Patient-derived Xenograft Model Market by End Use in 2019, 2024, and 2031
  • Figure 8.9: Trends of the North American Patient-derived Xenograft Model Market ($B) by End Use (2019-2024)
  • Figure 8.10: Forecast for the North American Patient-derived Xenograft Model Market ($B) by End Use (2025-2031)
  • Figure 8.11: Trends and Forecast for the United States Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the Mexican Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 8.13: Trends and Forecast for the Canadian Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the European Patient-derived Xenograft Model Market (2019-2031)
  • Figure 9.2: European Patient-derived Xenograft Model Market by Tumor Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the European Patient-derived Xenograft Model Market ($B) by Tumor Type (2019-2024)
  • Figure 9.4: Forecast for the European Patient-derived Xenograft Model Market ($B) by Tumor Type (2025-2031)
  • Figure 9.5: European Patient-derived Xenograft Model Market by Model Type in 2019, 2024, and 2031
  • Figure 9.6: Trends of the European Patient-derived Xenograft Model Market ($B) by Model Type (2019-2024)
  • Figure 9.7: Forecast for the European Patient-derived Xenograft Model Market ($B) by Model Type (2025-2031)
  • Figure 9.8: European Patient-derived Xenograft Model Market by End Use in 2019, 2024, and 2031
  • Figure 9.9: Trends of the European Patient-derived Xenograft Model Market ($B) by End Use (2019-2024)
  • Figure 9.10: Forecast for the European Patient-derived Xenograft Model Market ($B) by End Use (2025-2031)
  • Figure 9.11: Trends and Forecast for the German Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the French Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 9.13: Trends and Forecast for the Spanish Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 9.14: Trends and Forecast for the Italian Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 9.15: Trends and Forecast for the United Kingdom Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the APAC Patient-derived Xenograft Model Market (2019-2031)
  • Figure 10.2: APAC Patient-derived Xenograft Model Market by Tumor Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the APAC Patient-derived Xenograft Model Market ($B) by Tumor Type (2019-2024)
  • Figure 10.4: Forecast for the APAC Patient-derived Xenograft Model Market ($B) by Tumor Type (2025-2031)
  • Figure 10.5: APAC Patient-derived Xenograft Model Market by Model Type in 2019, 2024, and 2031
  • Figure 10.6: Trends of the APAC Patient-derived Xenograft Model Market ($B) by Model Type (2019-2024)
  • Figure 10.7: Forecast for the APAC Patient-derived Xenograft Model Market ($B) by Model Type (2025-2031)
  • Figure 10.8: APAC Patient-derived Xenograft Model Market by End Use in 2019, 2024, and 2031
  • Figure 10.9: Trends of the APAC Patient-derived Xenograft Model Market ($B) by End Use (2019-2024)
  • Figure 10.10: Forecast for the APAC Patient-derived Xenograft Model Market ($B) by End Use (2025-2031)
  • Figure 10.11: Trends and Forecast for the Japanese Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 10.12: Trends and Forecast for the Indian Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 10.13: Trends and Forecast for the Chinese Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 10.14: Trends and Forecast for the South Korean Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 10.15: Trends and Forecast for the Indonesian Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 11.1: Trends and Forecast for the ROW Patient-derived Xenograft Model Market (2019-2031)
  • Figure 11.2: ROW Patient-derived Xenograft Model Market by Tumor Type in 2019, 2024, and 2031
  • Figure 11.3: Trends of the ROW Patient-derived Xenograft Model Market ($B) by Tumor Type (2019-2024)
  • Figure 11.4: Forecast for the ROW Patient-derived Xenograft Model Market ($B) by Tumor Type (2025-2031)
  • Figure 11.5: ROW Patient-derived Xenograft Model Market by Model Type in 2019, 2024, and 2031
  • Figure 11.6: Trends of the ROW Patient-derived Xenograft Model Market ($B) by Model Type (2019-2024)
  • Figure 11.7: Forecast for the ROW Patient-derived Xenograft Model Market ($B) by Model Type (2025-2031)
  • Figure 11.8: ROW Patient-derived Xenograft Model Market by End Use in 2019, 2024, and 2031
  • Figure 11.9: Trends of the ROW Patient-derived Xenograft Model Market ($B) by End Use (2019-2024)
  • Figure 11.10: Forecast for the ROW Patient-derived Xenograft Model Market ($B) by End Use (2025-2031)
  • Figure 11.11: Trends and Forecast for the Middle Eastern Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 11.12: Trends and Forecast for the South American Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 11.13: Trends and Forecast for the African Patient-derived Xenograft Model Market ($B) (2019-2031)
  • Figure 12.1: Porter's Five Forces Analysis of the Global Patient-derived Xenograft Model Market
  • Figure 12.2: Market Share (%) of Top Players in the Global Patient-derived Xenograft Model Market (2024)
  • Figure 13.1: Growth Opportunities for the Global Patient-derived Xenograft Model Market by Tumor Type
  • Figure 13.2: Growth Opportunities for the Global Patient-derived Xenograft Model Market by Model Type
  • Figure 13.3: Growth Opportunities for the Global Patient-derived Xenograft Model Market by End Use
  • Figure 13.4: Growth Opportunities for the Global Patient-derived Xenograft Model Market by Region
  • Figure 13.5: Emerging Trends in the Global Patient-derived Xenograft Model Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Patient-derived Xenograft Model Market by Tumor Type, Model Type, and End Use
  • Table 1.2: Attractiveness Analysis for the Patient-derived Xenograft Model Market by Region
  • Table 1.3: Global Patient-derived Xenograft Model Market Parameters and Attributes
  • Table 3.1: Trends of the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 3.2: Forecast for the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Patient-derived Xenograft Model Market by Tumor Type
  • Table 4.2: Market Size and CAGR of Various Tumor Type in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Tumor Type in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 4.4: Trends of Lung Cancer in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 4.5: Forecast for Lung Cancer in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 4.6: Trends of Pancreatic Cancer in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 4.7: Forecast for Pancreatic Cancer in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 4.8: Trends of Prostate Cancer in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 4.9: Forecast for Prostate Cancer in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 4.10: Trends of Breast Cancer in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 4.11: Forecast for Breast Cancer in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 4.12: Trends of Others in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 4.13: Forecast for Others in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Patient-derived Xenograft Model Market by Model Type
  • Table 5.2: Market Size and CAGR of Various Model Type in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Model Type in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 5.4: Trends of Mice Model in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 5.5: Forecast for Mice Model in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 5.6: Trends of Rat Model in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 5.7: Forecast for Rat Model in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 6.1: Attractiveness Analysis for the Global Patient-derived Xenograft Model Market by End Use
  • Table 6.2: Market Size and CAGR of Various End Use in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 6.3: Market Size and CAGR of Various End Use in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 6.4: Trends of Pharmaceutical & Biopharmaceutical Companies in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 6.5: Forecast for Pharmaceutical & Biopharmaceutical Companies in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 6.6: Trends of Academic & Research Institutes in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 6.7: Forecast for Academic & Research Institutes in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 6.8: Trends of CRO's & CDMO's in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 6.9: Forecast for CRO's & CDMO's in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 7.1: Market Size and CAGR of Various Regions in the Global Patient-derived Xenograft Model Market (2019-2024)
  • Table 7.2: Market Size and CAGR of Various Regions in the Global Patient-derived Xenograft Model Market (2025-2031)
  • Table 8.1: Trends of the North American Patient-derived Xenograft Model Market (2019-2024)
  • Table 8.2: Forecast for the North American Patient-derived Xenograft Model Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Tumor Type in the North American Patient-derived Xenograft Model Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Tumor Type in the North American Patient-derived Xenograft Model Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Model Type in the North American Patient-derived Xenograft Model Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Model Type in the North American Patient-derived Xenograft Model Market (2025-2031)
  • Table 8.7: Market Size and CAGR of Various End Use in the North American Patient-derived Xenograft Model Market (2019-2024)
  • Table 8.8: Market Size and CAGR of Various End Use in the North American Patient-derived Xenograft Model Market (2025-2031)
  • Table 8.9: Trends and Forecast for the United States Patient-derived Xenograft Model Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Mexican Patient-derived Xenograft Model Market (2019-2031)
  • Table 8.11: Trends and Forecast for the Canadian Patient-derived Xenograft Model Market (2019-2031)
  • Table 9.1: Trends of the European Patient-derived Xenograft Model Market (2019-2024)
  • Table 9.2: Forecast for the European Patient-derived Xenograft Model Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Tumor Type in the European Patient-derived Xenograft Model Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Tumor Type in the European Patient-derived Xenograft Model Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Model Type in the European Patient-derived Xenograft Model Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Model Type in the European Patient-derived Xenograft Model Market (2025-2031)
  • Table 9.7: Market Size and CAGR of Various End Use in the European Patient-derived Xenograft Model Market (2019-2024)
  • Table 9.8: Market Size and CAGR of Various End Use in the European Patient-derived Xenograft Model Market (2025-2031)
  • Table 9.9: Trends and Forecast for the German Patient-derived Xenograft Model Market (2019-2031)
  • Table 9.10: Trends and Forecast for the French Patient-derived Xenograft Model Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Spanish Patient-derived Xenograft Model Market (2019-2031)
  • Table 9.12: Trends and Forecast for the Italian Patient-derived Xenograft Model Market (2019-2031)
  • Table 9.13: Trends and Forecast for the United Kingdom Patient-derived Xenograft Model Market (2019-2031)
  • Table 10.1: Trends of the APAC Patient-derived Xenograft Model Market (2019-2024)
  • Table 10.2: Forecast for the APAC Patient-derived Xenograft Model Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Tumor Type in the APAC Patient-derived Xenograft Model Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Tumor Type in the APAC Patient-derived Xenograft Model Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Model Type in the APAC Patient-derived Xenograft Model Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Model Type in the APAC Patient-derived Xenograft Model Market (2025-2031)
  • Table 10.7: Market Size and CAGR of Various End Use in the APAC Patient-derived Xenograft Model Market (2019-2024)
  • Table 10.8: Market Size and CAGR of Various End Use in the APAC Patient-derived Xenograft Model Market (2025-2031)
  • Table 10.9: Trends and Forecast for the Japanese Patient-derived Xenograft Model Market (2019-2031)
  • Table 10.10: Trends and Forecast for the Indian Patient-derived Xenograft Model Market (2019-2031)
  • Table 10.11: Trends and Forecast for the Chinese Patient-derived Xenograft Model Market (2019-2031)
  • Table 10.12: Trends and Forecast for the South Korean Patient-derived Xenograft Model Market (2019-2031)
  • Table 10.13: Trends and Forecast for the Indonesian Patient-derived Xenograft Model Market (2019-2031)
  • Table 11.1: Trends of the ROW Patient-derived Xenograft Model Market (2019-2024)
  • Table 11.2: Forecast for the ROW Patient-derived Xenograft Model Market (2025-2031)
  • Table 11.3: Market Size and CAGR of Various Tumor Type in the ROW Patient-derived Xenograft Model Market (2019-2024)
  • Table 11.4: Market Size and CAGR of Various Tumor Type in the ROW Patient-derived Xenograft Model Market (2025-2031)
  • Table 11.5: Market Size and CAGR of Various Model Type in the ROW Patient-derived Xenograft Model Market (2019-2024)
  • Table 11.6: Market Size and CAGR of Various Model Type in the ROW Patient-derived Xenograft Model Market (2025-2031)
  • Table 11.7: Market Size and CAGR of Various End Use in the ROW Patient-derived Xenograft Model Market (2019-2024)
  • Table 11.8: Market Size and CAGR of Various End Use in the ROW Patient-derived Xenograft Model Market (2025-2031)
  • Table 11.9: Trends and Forecast for the Middle Eastern Patient-derived Xenograft Model Market (2019-2031)
  • Table 11.10: Trends and Forecast for the South American Patient-derived Xenograft Model Market (2019-2031)
  • Table 11.11: Trends and Forecast for the African Patient-derived Xenograft Model Market (2019-2031)
  • Table 12.1: Product Mapping of Patient-derived Xenograft Model Suppliers Based on Segments
  • Table 12.2: Operational Integration of Patient-derived Xenograft Model Manufacturers
  • Table 12.3: Rankings of Suppliers Based on Patient-derived Xenograft Model Revenue
  • Table 13.1: New Product Launches by Major Patient-derived Xenograft Model Producers (2019-2024)
  • Table 13.2: Certification Acquired by Major Competitor in the Global Patient-derived Xenograft Model Market